Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Double Q-Learning for Intelligent Multi-Drug Scheduling in Cancer Chemotherapy Optimisation.

Created on 04 Aug 2026

Authors

Behnoush Alizade, Ahmad Hajipour

Published in

IET systems biology. Volume 20. Issue 1. Pages e70083.

Abstract

Chemotherapy scheduling poses a challenging control problem due to the need to suppress tumour growth whilst maintaining systemic toxicity within clinically acceptable limits. This study develops a double Q-learning-based controller for optimising daily dosing of a three-drug regimen consisting of cisplatin, docetaxel and irinotecan. A pharmacokinetics-pharmacodynamics (PK/PD) tumour model with eight resistance states is used as the simulation environment. The controller aims to minimise tumour burden whilst enforcing strict toxicity constraints aligned with clinical dosing guidelines. Simulation results show that double Q-learning substantially outperforms classical Q-learning, achieving near-complete tumour suppression within the simulation framework, corresponding to a residual tumour fraction on the order of 1 0 - 6 (approximately six orders of magnitude reduction) whilst maintaining toxicity within predefined constraints. Robustness analyses under physiological parameter variations of up to ± 50 % and under abrupt disturbance events further demonstrate that the double Q-learning policy preserves stable closed-loop behaviour within the simulation environment and exhibits strong resilience to uncertainty. Overall, the results indicate that double Q-learning provides a proof-of-concept framework for adaptive chemotherapy optimisation, with potential for future investigation in reinforcement learning-based chemotherapy optimisation frameworks.

PMID:
42546316
Bibliographic data and abstract were imported from PubMed on 04 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 5
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement